X
Pfizer moves haemophilia gene therapy into phase 3
https://pharmaphorum.com/r-d/pfizer-haemophilia-b-gene-therapy/
haemophilia B
After losing out on two big deals, Sanofi to buy Bioverativ for $11.6bn
French pharma makes move into haemophilia market.
Spark and Pfizer’s haemophilia gene therapy gets European PRIME status
Decision based on promising data from ongoing phase 1/2 trial.
